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Preface 
 
 
Natural products have played an important role in health care and disease prevention, and many 
useful drugs are developed from nature sources. According to the World Health Organization 
(WHO), 80% of the population of the world depends on traditional medicine for primary health 
care.
1
 Natural products also essential role in therapeutic agent, and presently at least 119 chemicals, 
derived from 90 plant species, can be considered as important drugs. Figure I show a graphical 
representation of the contribution of natural products to drug discovery.
2
 In addition, the variation of 
approved drugs, which were from natural products and natural products-derived, is shown on Figure 
II.  
 
 
 
 
 
 
 
 
 
 
Figure I Sources of drugs 
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Figure II Variation of natural product and natural product-derived approved drugs 
 
 
 
A number of drug candidates are derived from various naturally occurring medicinal sources. It can 
be divided into four classes; microorganism, plant, marine, and animal. Among these, plants 
contributed in the treatment of disease as medicines. Ingenol 3-O-angelate
3
 isolated from Euphorbia 
peplus which is a potential chemotherapeutic agent for skin cancer. Podophyllotoxin
4
 obtained as an 
anticancer agent from Podophyllum peltatum in 1944. Etoposide and teniposide,
5
 a semisynthetic 
derivative of podophyllotoxin, cause cell death by inhibition of topoisomerase II. Thus both these 
compounds are used in the treatment of various cancers. The most generally used anticancer drug is 
paclitaxel (Taxol® ),
3
 which was obtained from Taxus brevifolia (Pacific Yew), and it was approved 
by Food and Drug Administration (FDA) (Figure III). 
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Figure III Plant based anticancer drugs 
 
 
The discovery of natural drugs is guided by bioassay. It can be used to detect the bioactivity of the 
extracts, thus the selection of extracts guide for further study. In the isolation steps the bioassay will 
lead the crude fraction towards to pure compounds. Accordingly, bioassay should be simple, rapid, 
and reliable.  
 
The therapeutics development targeting to various human diseases are still in initial stage of study. 
Thus, discovery of compounds derived from natural products would be potential therapeutic drug to 
human diseases.  
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Chapter 1 
 
 
Introduction 
 
 
The Wnt signaling pathway, which is highly conserved throughout evolution from metazoan to 
human, plays key roles in the regulation of numerous cellular processes, including embryonic 
development, differentiation, proliferation, survival, polarity, migration and specification of cell fate 
in various cells.
1
 However, abnormal activation of the Wnt signaling is critical factor in oncogenesis 
in many types of cancer,
2,3
 particularly in human colon cancer. In previous study, up to 80% of 
colon cancer was caused by aberrant activation of the Wnt signaling. Therefore, Wnt signaling is 
considered as an attractive therapeutic target for colon cancer. Furthermore, recent studies revealed 
that this signaling pathway may play a significant role in cancer stem cells.
4,5
 The Wnt signaling 
supports differentiation of cancer stem cells as well as formation and maintenance of stem cells. 
Deregulation of this pathway also associated with various human diseases including diabetes, 
osteoporosis, and Alzheimer’s disease.1,2  
Therefore, natural products have recently become an important source of small molecule chemical 
entities that regulate Wnt signaling pathway. Examples of natural products and natural product-
derived compounds that have been found to inhibit Wnt signaling are illustrated in Figure 1.2. The 
screening study to identify the small-molecule inhibitors of the Wnt signaling from synthetic 
compounds library and natural products collection has gain in popularity.
3
  
Wnt pathway classify into two branches; (1) non-canonical and (2) canonical (β-catenin-dependent) 
signaling.  
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Non-canonical signaling is independent of β-catenin, for instance, Wnt/jun N-terminal kinase (JNK) 
pathway or the Wnt/Ca
2+
 pathway. In the JNK pathway, frizzled activates JNK and asymmetric 
cytoskeletal organization coordinated polarization of cells. The Wnt/Ca2
+
 pathway lead to release of 
intracellular Ca2
+
 and activates calcium dependent enzymes like calcium/calmodulin-dependent 
kinase (CaMK)II, PKC or calcineurin.
6
  
 
In contrast, canonical Wnt pathway involves multifunctional protein β-catenin (Figure 1.1). In the 
absence of Wnt, β-catenin is targeted to destruction complex for its phosphorylation. Destruction 
complex formed by adenomatous polyposis coli (APC), axin, casein kinase 1α (CK1α), and 
glycogen synthase kinase 3β (GSK3β). Phosphorylation of β-catenin accomplished through CK1α-
mediated phosphorylation at Ser 45, subsequently Ser 33, Ser 37, Thr 41 phosphorylation by 
GSK3β. The phosphorylated β-catenin is poly-ubiquitylated and recognized by F-box β-transducin 
repeat containing protein (β-TrCP) to lead degradation via proteasome.  
 
In the presence of Wnt ligands, Wnt binding to frizzled (Fzd)-LRP receptor results in inhibition of 
β-catenin phosphorylation and this allows accumulation of β-catenin. Stabilized β-catenin enter the 
nuleus and bind to T cell factor (TCF)/lymphoid enhancer factor (LEF) family of transcription 
factors, leading to activation of Wnt/β-catenin target genes such as c-myc and cyclinD1.7  
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Figure 1.1 Canonical Wnt signaling pathway 
 
Numerous human cancers including breast cancer, melanoma, and carcinoma also show aberrant 
Wnt signaling activity, even though with a low possibility than colorectal cancer. As for colorectal 
cancer, abnormal regulation of Wnt signaling usually occurs owing to mutation of APC.
8,9
 Whereas 
mutation of β-catenin leads to a functional disorder of Wnt signaling in cancer include skin cancer, 
liver cancer, and prostate cancer.  
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Figure 1.2 Small-molecule inhibitors that target Wnt signaling at different levels 
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A number of small-molecules were identified to regulate Wnt signaling include niclosamide
10
 for 
frizzled, NSC668036
11
 for Dsh, pyrvinium
12
 for CK1, IWR-1
13
 and XAV939
14
 for Axin, SB-
216763
15
 and BIO (6-bromoindirubin-3’-oxime)16 for GSK3, 2,4-diamino-quinazoline,17 PKF115-
584,
18
 quercetin
19
 and ICG-001
20
 for β-catenin and its binding to TCF or CREB. In addition, the 
biological effects of some natural compounds on Wnt signaling in various cancer cells were 
identified.
7,21-22
 EGCG ((-1)-Epigallocatechin-3-Gallate)
23
 is derived from green tea and is reported 
to inhibit Wnt signaling in diverse cancer cells such as breast cancer, lung cancer, gastrointestinal 
cancer, and nasopharyngeal cancer. Quercetin showed that significant activity against colon 
cancer,
24
 and curcumin have been reported to inhibit the proliferation of several types of cancer 
cells.
25
  
 
Recently, our group looks into natural resources to search for bioactive natural products with Wnt 
signaling inhibitory activities, and identified several active compounds as lycogarubin B, nonactin, 
and isoeleutherine. Lycogarubin B and nonactin isolated from actinomycete strains, and 
isoeleutherine isolated from extracts of Eleutherine palmifolia plants, showed inhibition of TCF 
transcription.
26-28 
 
 
 
Figure 1.3 Small-molecule inhibitors that target Wnt signaling isolated by our laboratory 
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In this research, we searched small-molecule derived from natural resources which inhibit Wnt 
signaling pathway. To screen natural products, TOP activity, which use a luciferase reporter gene, 
and viability was measured. According to screening program, Calotropis gigantea (Bangladesh), 
Bauhinia malabarica (Thai), and Urginea indica (Bangladesh) were selected and active compounds 
were isolated by activity-guide for further. 
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Chapter 2 
 
 
Assay protocol 
 
 
2.1  TCF/β-catenin Transcriptional Activity Assay 
 
Luciferase assay was developed for reporter quantitation in mammalian cells. Light is produced by 
converting the chemical energy of luciferin oxidation through an electron transition, forming the 
product molecule oxyluciferin.  
 
 
 
 
 
 
 
 
 
Figure 2.1 Bioluminescent reaction catalyzed by firefly luciferase 
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Firefly luciferase, a monomeric 61kDa protein, catalyzes luciferin oxidation using ATP·Mg
2+
 as a 
co-substrate.  
 
TCF/β-catenin transcriptional activity assay is important for a substantial amount of the early 
characterization of the pathway. We used cell-based reporter luciferase assay which called TOPflash 
assay to evaluate TCF/β-catenin transcriptional activity (Figure 2.4). STF/293 cells stably 
transfected with SuperTOPflash plasmid containing seven TCF/LEF binding sites (CCTTTGATC) 
upstream of TA promoter were used in this assay. LiCl, as an inhibitor of GSK3, was treated to 
activate Wnt signaling. In contrast, FOPflash has mutated copies of TCF/LEF binding sites 
(CCTTTGGCC) and it is used for measuring nonspecific activation of the reporter. FOPflash 
activities were quantified by measuring firefly luciferase activities, and normalized to the renila 
luciferase activities (Figure 2.5).
1 
 
 
 
 
 
 
 
 
 
Figure 2.2 pSuperTOPflash vetor and pSuperFOPflash vetor 
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For TOP assay, STF/293 cells were seeded into 96-well plate. After 24 h incubation, cells were 
treated with sample and LiCl. An additional 24 h incubation, cells were lysed and luciferase 
activities were measured (Figure 2.3). In this assay, quercetin (IC50 30.4 μM)
1
 was used as an 
positive control which was known as an inhibitor of TCF/β-catenin transcription. 
 
 
 
 
 
 
 
Figure 2.3 Assay protocol of Wnt signaling inhibitory 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Assay system 
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Meanwhile, 293T cells were split into 24-well plates for FOPflash assay. After 24 h incubation, 
cells were transfected for 3 h with SuperFOPflash reporter plasmid using Lipofectamine 2000. 
Testing samples were added and an additional 24 h incubation is required to measured luciferase 
activity. The relative luciferase activities were calculated as a rate of Firefly luciferase 
activity/Renilla luciferase activity. The value of control (DMSO) was normalized to 100%. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Relative luciferase activity 
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Figure 2.6 Positive sample of transcriptional activity 
 
FOPflash, which has mutant binding sites, is not concerned with degradation or activation of 
luciferase. Hence, if the sample has low percentage of TOP activity, but the high percentage of FOP 
activity can be considered as positive. However if sample shows the high percentage of both TOP 
and FOP activity or low percentage of TOP and FOP activity should be considered as negative 
(Figure 2.6). 
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2.2 Cell Viability Assay 
 
The fluorometric microculture cytotoxicity assay (FMCA)
1
 method using Fluorescein Diacetate 
(FDA) as a dye, was used to measure the cell viability of samples. FDA is a nonfluorescent probe 
which is converted to fluorescent compound Fluirescein by esterase. The FMCA measures the 
esterase activity of cells with intact membrane by measuring fluorescence generated by hydrolyzed 
FDA. Thus the fluorescence intensity is directly proportional to the number of viable cells which is 
calculated as follows: 
 
 
 
 
 
 
 
 
 
Figure 2.7 The conversion by viable cells of fluorescein diacetate to fluorescent fluorescein 
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2.3 Compound Screen 
 
STF/293 cells were seeded in a 96-well white plate at 3×10
4 
cells per well. After 24 h incubation, 
cells were treated with LiCl and various concentration of testing samples. An additional 24 h 
incubation, luciferase activities were measured on a microplate luminometer (Thermo) using 
Luciferase Assay System (Promega) according to the manufacturer’s protocol. Simultaueously, the 
cell viability was measured by FMCA method. Cells were seeded in a 96-well black plate at 3×10
4 
cells per well. After 24 h incubation, medium was replaced with compounds. After additional 24 h 
incubation, medium was replaced with PBS containing FDA and incubated 1 h, 37°C. Fluorescence 
was determined by a fluorescence plate reader (Thermo). As shown in Figure 2.8, the bar graph 
represents luciferase activity and the line graph represents the viability of compounds. If the 
compound shows the high percentage of luciferase activity and viability or low percentage of 
luciferase activity and viability, should be considered negative sample. However, when the 
percentage of luciferase activity is low but the percentage of cell viability high, compound is 
considered to positively inhibit Wnt signaling pathway.  
 
 
 
 
 
 
 
 
Figure 2.8 Selection of Wnt signaling inhibitory activity compounds 
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2.4 Screening of Plant Extract Library 
 
Medicinal plants, collected from Thailand (KKP) and Bangladesh (KKB), were screened for Wnt 
signaling inhibitory activity. About 50 Thailand plants (KKP240-KKP247 and KKP251- KKP292) 
and 40 Bangladesh plants (KKB84-KKB123) were screened and activity of some selected extracts 
is shown in Figure 2.9. KKB50 Urginea indica, KKB69 Calotropis gigantea, and KKP240 
Bauhinia malabarica were selected for bioassay guided separation. Extracts library of Bangladesh 
and Thailand plants were screened by Ms. Naomi Mori and Mr. Kentaro Kamiya, respectively. The 
activity charts are attached in Appendix I, II. 
  
 22 
 
 
Figure 2.9 Screening library of plants extract from Bangladesh (KKB009: Sida acuta, KKB014: 
Physaris minima, KKB019: Cleome rutidosperma, KKB023: Xylocarpus granatum, KKB039: 
Amoora cucullata, KKB050: Urginea indica, KKB052: Pongamia pinnata, KKB053: Pongamia 
pinnata, KKB054: Ocimum gratissimum, KKB056: Pandanus foetidus, KKB062: Sida rhombifolia, 
KKB076: Rhus succedanea, KKB079: Baliospermum montanum) and Thai (KKP247: Limnocharis 
flava, KKP255: Oryza sativa (seed), KKP260: Zea mays, KKP261: Curcuma comosa, KKP262: 
Curcuma aromatica, KKP267: Dalbergia latifolia, KKP270: Dolichos lablab, KKP271: 
Pachyrhizus erosus, KKP272: Pueraria hirsute, KKP274: Borassus flabellifer, KKP281: Erythrina 
variegate, KKP283: Casuarina equisetifolia, KKP287: Artocarpus communis).  
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Chapter 3 
 
 
Separation of Calotropis gigantea 
 
 
Calotropis gigantea is commonly known as milkweed or swallow-wort. It’s belongs to the family 
Asclepiadaceae and widely distributed in Bangladesh, India, Burma, and Pakistan. This plant used 
as traditional medicinal plant with unique properties. Traditionally Calotropis is used alone or with 
other medicines to treat common disease such as analgesic activity, wound healing activity,
1
 
Ehrlich’s ascites carcinoma,2 and antimicrobial activity.3 The identified phytochemicals in this plant 
are flavonol glycosides,
4
 pregnanone,
5
 sterols and mixture of tetracyclic triterpene compounds.
6
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Calotropis gigantea 
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3.1 Extraction and Isolation 
 
The exudate of C.gigantea was extracted with MeOH. The MeOH extract (60 g) was suspended in 
10% aqueous MeOH and partitioned with n-hexane (5.5 g), EtOAc (21 g), and water (18.6 g), 
successively. Each fraction was then evaluated for inhibition of TCF/β-catenin transcription (hexane 
Layer, 0% inhibition; EtOAc Layer, 89% inhibition at 0.1 μg/mL, respectively). Column 
chromatography was performed to isolate the active compounds from the EtOAc soluble fraction. 
The EtOAc soluble fraction was column chromatographed on a silica gel PSQ 100B (φ70 x 500 
mm) using gradient elution with CHCl3:MeOH (10:1 to 5:5), in order to divide into six fractions (Fr. 
1A- Fr. 1F). Fr. 1C (10 g, 99% inhibition at 0.1 μg/mL) was chromatographed on silica gel column 
(φ70 x 500 mm) resulting in seven subfractions. Fr. 2F (3.2 g, 37% inhibition at 0.1 μg/mL) was 
fractionated by ODS column (φ20 x 900 mm) by elution with MeOH:H2O (5:5 to 10:0) to give 1 
(109.1 mg). Compound 2 (34.9 mg) was isolated through ODS column (φ30 x 350 mm) of Fr. 3C 
by elution with MeOH:H2O (7:3). Fr. 4D (37.8 mg, 91% inhibition at 0.1 μg/mL) was subjected to 
chromatography on a silica gel column (φ40 x 300 mm) with CHCl3:MeOH (22:1) to give 3 (8.7 
mg). Fr. 4C (128 mg, 75% inhibition at 0.1 μg/mL) also separated using a silica gel column (φ30 x 
350 mm) with CHCl3:MeOH (19:1) to give 4 (36 mg) and 5 (3.8 mg). Fr. 3B (350 mg, 81 % 
inhibition at 0.1 μg/mL) was isolated through additional ODS column chromatography (φ30 x 300 
mm) by elution with MeOH:H2O (8:2, 7:3) to give 6 (7.8 mg). 
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Figure 3.2 Activity-guided isolation scheme of Calotropis gigantea 
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3.2  Structure Elucidation 
 
Separation of Calotropis gigantea guided by Wnt signaling inhibition led to the isolation of 6 
cardenolides (1-6). All isolated compounds had aldehyde at C-19, and sugar was attachment to C-2 
and C-3 positions of the cardenolide aglycone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Structure of compounds 1-6 
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Uscharin (1)
7
 
ESIMS m/z 588 [M+H]
+
; [α]24D +20.2 (c 1.0, CHCl3) (lit.
14
 [α]22D +37.8, CHCl3), 
1
H and 
13
C NMR 
data, see Table 3.1 and Table 3.3 
 
Asclepin (2)
8
 
ESIMS m/z 573 [M-H]
–; [α]24D +10.0 (c 1.0, CHCl3) (lit.
8
 [α]D +10, CHCl3), 
1
H NMR data, see Table 
3.2 
 
2”-oxovoruscharin (3)9 
ESIMS m/z 602 [M-H]
-
; [α]24D  -14.6 (c 0.8, CHCl3), 
1
H NMR data, see Table 3.1 
 
Calotropin (4)
7
 
ESIMS m/z 531 [M-H]
–
; [α]24D +60.9 (c 1.0, MeOH) (lit.
10
 [α]D +65.3, MeOH), 
1
H and 
13
C NMR 
data, see Table 3.2 and Table, 3.3 
 
Voruscharin (5)
7
 
ESIMS m/z 590 [M+H]
+; [α]24D+ 53.9 (c 0.3, EtOH) (lit.
14
 [α]22D+ 60.7, EtOH), 
1
H and 
13
C NMR data, 
see Table 3.1 and Table 3.3 
 
Uscharidin (6)
10
 
ESIMS m/z 529 [M-H]
–; [α]24D +27.0 (c 0.6, EtOH) (lit.
14
 [α]D +25.6, EtOH), 
1
H NMR data, see 
Table 3.2 
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Table 3.1 NMR spectroscopic data for 1, 3, 5 
 
 
 
 
 
 
 
 
 
 
Table 3.2 NMR spectroscopic data for 2, 4, 6 
  
  Compound 1 Compound 3 Compound 5 
position δH (J in Hz) δH (J in Hz) δH (J in Hz) 
18 0.73 (3H, s) 0.88 (3H, s) 0.73 (3H, s) 
19 9.93 (1H, s) 9.90 (1H, s) 9.98 (1H, s) 
1' 5.57 (1H, s) 5.00 (1H, s) 4.72 (1H, s) 
2'       
3'       
4' 2.33 (2H, dd, 4.4, 12.8) 1.97-2.11 (2H, m) 1.84-2.09 (2H, m) 
5'     4.21 (1H, m) 
6' 1.10 (3H, d, 6.4) 1.26 (3H, d, 6) 1.23 (3H, s) 
1" 3.93  3.60 (2H, s)    
2" 7.45 (1H, s)  
 
  
NH   8.71   
  Compound 2 Compound 4 Compound 6 
position δH (J in Hz) δH (J in Hz) δH (J in Hz) 
18 0.80 (3H, s) 0.80 (3H, s) 0.80 (3H, s) 
19 9.99 (1H, s) 10.0 (1H, s) 9.99 (1H, s) 
1' 4.61 (1H, s) 4.56 (1H, s) 4.61 (1H, s) 
2'       
3' 4.76 (1H, m) 3.87-3.96 (1H, m)   
4'     2.74 (2H, m) 
5' 3.6-4.1 (1H, m) 3.61 (1H, m) 3.68 (1H, s) 
6' 1.28 (3H, s) 1.30 (3H, s) 1.40 (1H, s) 
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Table 3.3 NMR spectroscopic data for 1, 4-5 
 
 
 
 
 
  
  Compound 1 Compound 4 Compound 5 
position δC δC δC 
1 36.7  36.9 36.9 
2 68.5  70.2 69.5 
3 72.0  73.3 70.1 
4 32.6  32.8 32.7 
5 43.5  44.4 43.3 
6 28.0  28.8 28.5 
7 27.9  28.6 27.7 
8 42.6  43.4 42.9 
9 48.6  48.6 48.7 
10 53.0  54 51.8 
11 21.4  23 21.3 
12 39.3  40.2 39.3 
13 49.8  50.7 49.1 
14 84.1  85.7 85.5 
15 33.9  34.4 34.5 
16 27.2  27.9 27.6 
17 51.2  51.9 49.4 
18 15.9  16.1 16.1 
19 208.0  209.4 209.5 
20 175.8  178.2 174.6 
21 73.8  75.3 73.4 
22 117.9  117.9 118.4 
23 174.6  177.2 175 
1' 96.8  97.3 94.8 
2' 100.1  92.7 92.8 
3' 93.1  73.9 85.7 
4' 43.7  39.6 44.5 
5' 70.3  69.4 70.1 
6' 22.2  21.3 21.2 
1” 48.7    49.6  
2” 160.8    34.5 
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3.3  Activity Assay 
 
TCF/β-catenin transcriptional inhibitory 
 
The isolated compounds 1-6 were evaluated for their TCF/β-catenin transcriptional activity. Cells 
were exposed to 1, 5, and 10 nM of compounds. As shown in Figure 3.3, tested compounds 
exhibited strong inhibition of TOPflash activity with IC50 values of 1.3, 3.8, 1.1, 1.8, 1.0, and 0.7 
nM, respectively (Table 3.4), without significant FOP decrease (Figure 3.4). Although 1 and 2 
showed low cell viability in STF/293 cells, which were employed in TOPflash assay, at the 
concentration around IC50 of TOPflash assay, 3-6 did not cause potent decrease of viability (>60%) 
at the concentration around IC50 of TOPflash assay. Thus, 3-6 were revealed to be potent TCF/β-
catenin transcriptional inhibitors. 
 
Table 3.4 IC50 values of TOP assay 
 
 
 
  
  IC50 values (nM) 
1 1.3  
2 3.8  
3 1.1  
4 1.8  
5 1.0  
6 0.7  
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Figure 3.4 Inhibition of TCF/β-catenin transcriptional activity of 1-6. Compounds were treated on 
STF/293 cells for TOP assay and 293T cells for FOP assay. The bars indicated the s.d. 
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Cytotoxicity against colon cancer cells 
 
Compounds 1-6 were treated on colorectal cancer cell lines. Inhibition of Wnt signaling can 
decrease the viability of Wnt-dependent cancer cell lines. APC mutant colon cancer cell lines 
SW480 and DLD1
11
 and β-catenin mutant HCT11611, 12 were chosen for dependence on Wnt 
signaling as well as RKO colon cancer cells which are known to be independent Wnt signaling.
13
 
As shown in Figure 3.5, compounds 1-6 exhibited inhibition of cell viability for Wnt dependent cell 
lines compared with RKO cells. Interestingly, RKO cancer cells growth was not affected by 
compounds, indicating that 1-6 showed selective cytotoxicity on Wnt dependent cells in a different 
type of colon cancer cells. IC50 values of cytotoxicity are shown on Table 3.5. 
 
 
 
Figure 3.5 Cytotoxicity on Wnt-dependent colon cancer cells (SW480, DLD1, HCT116) and Wnt-
independent colon cancer cells (RKO). The bars indicated the s.d. 
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Table 3.5 IC50 values of cytotoxicity against Wnt-dependent cancer cells (SW480, DLD1, HCT116), 
and Wnt-independent cells (RKO) 
 
  IC50 values (nM) 
  1 2 3 4 5 6 
SW480 7.0  >10 3.1  2.6  3.4  2.4  
DLD1 2.8  5.5  2.1  2.0  2.6  1.8  
HCT116 6.0  >10 1.9  2.0  2.9  1.8  
RKO >10 >10 >10 >10 >10 >10 
 
 
In conclusion, six cardenolides compounds were isolated from Calotropis gigantea exudates guided 
by TCF/β-catenin transcriptional activity. All tested compounds exhibited strong TCF/β-catenin 
transcriptional inhibitory activity. Compounds 1 and 2 showed cytotoxicity against STF/293 cells, 
however, 3-6 did not showed significant decrease. Furthermore, isolated compounds (1-6) were 
cytotoxic against Wnt-dependent colon cancer cells, but did not affect on Wnt-independent colon 
cancer cells.  
  
 35 
 
References 
1. Deshmukh, P. T.; Fernandes, J.; Atul, A.; Toppo, E. J. Ethnopharm. 2009, 125, 178-181. 
2. Habib, M. R.; Aziz, M. A.; Karim, M. R. J. Appl. Biomed. 2010, 8, 47-54. 
3. Nenaah, G. World J. Microbiol Biotechnol. 2013, 29, 1255-1262. 
4. Sen, S.; Sahu, N. P.; Mahato, S. B. Phytochemistry 1992, 31, 2919-2921. 
5. Wang, Z. N.; Wang, M. Y.; Mei, W. L.; Han, Z.; Dai, H. F. Molecules 2008, 13, 3033-3039. 
6 Kumar, P. S.; Chezhian, A.; Raja, P. S.; Sathiyapriya, J. Bangladesh J. Pharmacol. 2012, 7, 
1-5. 
7. Cheung, H. T. A.; Chiu, F. C. K.; Watson, T. R.; Wells, R. J. J. Chem. Soc., Perkin Trans. I 
1983, 2827-2835. 
8. Singh, B.; Rastogi, R. P. Phytochemistry 1972, 11, 752-762. 
9. Van Quaquebake, E.; Simon, G.; Andre, A.; Dewelle, J.; El Yazidi, M.; Bruyneel, F.; Tuti, J.; 
Nacoulma, O.; Guissou, P.; Decaestecker, C. Braekman, J. C.; Kiss, R.; Darro, F. J. Med. 
Chem. 2005, 48, 849-856. 
10. Brusheweiler, F.; Stockel, K.; Reichstein, T. Helv. Chim. Acta. 1969, 52, 2276-2303. 
11. Yang, J.; Zhang, W.; Evans, P. M.; Chen, X.; He, X.; Liu, C. J. Biol. Chem. 2006, 281, 
17751-17757. 
12. Ilyas, M.; Tomlinson, I. P. M.; Rowan, A.; Pignatelli, M.; Bodmer, W. F. Proc. Natl. Acad. 
Sci. 1997, 94, 10330-10334. 
13. Waaler, J.; Machon, O.; Tumova, L.; Dinh, H.; Korinek, V.; Wilson Steven, R.; Paulsen Jan, 
E.; Pedersen Nina, M.; Eide Tor, J.; Machonova, O.; Gradl, D.; Voronkov, A.; von Kries 
Jens, P.; Krauss, S. Cancer Res. 2012, 72, 2822-2832. 
14. Seiber, J. N.; Nelson, C. J.; Lee, S. M. Phytochemistry 1982, 21, 2343-2348. 
  
 36 
 
Chapter 4 
 
 
Separation of Bauhinia malabarica 
 
 
The leaves of Bauhinia malabarica, inhabit in Thailand, belongs to caesalpiniaceae family. 
Baunihia malabarica has been used in traditional Thai medicine to promote wound healing, as a 
diuretic, to fight dysentery and as an emmenagogue.
1
 Several compounds including flavonols,
1
 
racemosol,
2
 and fatty acid
3
 have been isolated from Bauhinia malabarica. 
 
 
 
 
 
 
 
 
 
  
 
Figure 4.1 Bauhinia malabarica 
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4.1 Extraction and Isolation 
 
The dried leaves of B. malabarica (268.7 g) were extracted with MeOH. The MeOH extract (50 g) 
was suspended in 10% aqueous MeOH and partitioned with hexane (200 mLⅹ3), EtOAc (200 mL
ⅹ3), n-BuOH (200 mLⅹ3), and finally water. Each fraction was then evaluated for inhibition of 
TCF/β-catenin transcription (hexane layer, 12 g, 50.9 % inhibition; EtOAc layer, 3 g, 39.3 % 
inhibition; n-BuOH layer, 10 g, 51.2 % inhibition at 10 μg/mL, respectively). Column 
chromatography was performed to isolate the active compounds from the EtOAc layer.  
 
 
Figure 4.2 Activity-guided isolation scheme of Bauhinia malabarica 
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The EtOAc layer was separated by a silica gel (PSQ 100B, φ40ⅹ600 mm) using a gradient of 
CHCl3:MeOH (9.5:0.5 to 1:9), in order to divide it into fifteen fractions (Fr. 1A- Fr. 1O). Fr. 1C 
(17.9 mg, 43% inhibition at 5 μg/mL) was subjected to chromatography on an ODS column (φ29ⅹ
320 mm) with MeOH to give 7 (9.9 mg). Fr. 1K (93.3 mg, 27.5% inhibition at 5 μg/mL) was also 
separated using an ODS column (φ29ⅹ320 mm) but with MeOH:H2O (7:3) to give 8 (13.4 mg). Fr. 
1M (204.5 mg, 46.8% inhibition at 5 μg/mL) was separated using an ODS column (φ29ⅹ320 mm) 
by elution with MeOH:HsO (7:3) to afford seven sub-fractions (Fr. 5A- Fr. 5G), and 9 (as Fr. 5F, 2.6 
mg). Compound 10 (14.5 mg) was isolated using an additional ODS column (φ29ⅹ320 mm) from 
Fr. 5B (53 mg) with MeOH:H2O (6:4). Fr. 1G (45 mg, 31.5% inhibition at 5 μg/mL) was re-
chromatographed on an ODS column (φ29ⅹ320 mm) with MeOH:H2O (6:4) to give 11 (1.3 mg). 
 
4.2  Structure Elucidation 
 
Bioassay-guided separation of Bauhinia malabarica led to the isolation of β-sitosterol and four 
flavonoids from EtOAc layer. Compounds 7-11 were identified by comparing their spectral data 
with values in the literature values. Among these compounds, 9 and 11 had two methyl groups at C-
6 and C-8. 
 
β-sitosterol (7)4 
ESIMS m/z 413 [M-H]
-
; 
1
H and 
13
C NMR data, see Table 4.1 
 
Quercetin (8)
5
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ESIMS m/z 303 [M+H]
+
, 
1
H NMR data, see Table 4.2 
 
6,8-C-dimethyl kaempferol-3-O-rhamnopyranoside (9)
6
 
ESIMS m/z 461 [M+H]
+
, [α]24D -63.9 (c 0.5, MeOH) (lit.
6
 [α]24D -131, MeOH) , 
1
H and 
13
C NMR data, 
see Table 4.1 
 
Hyperin (10)
5
 
ESIMS m/z 465 [M+H]
+
, [α]24D +32.2 (c 0.3, MeOH), 
1
H NMR data, see Table 4.2 
 
6,8-C-dimethyl kaempferol 3-mehtyl ether (11)
7
 
ESIMS m/z 329 [M+H]
+
, 
1
H NMR data, see Table 4.2 
 
 
Figure 4.3 Structure of compounds 7-11 
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Table 4.1 NMR spectroscopic data for 7, 9 
 
  Compound 7 
 
  Compound 9 
position δC δH (J in Hz) 
 
position δC δH (J in Hz) 
1 37.3   
 
2 157.6    
2 31.7   
 
3 136.0    
3 71.3 3.50 (1H, m) 
 
4 179.9    
4 42.3   
 
5 161.6    
5 140.8   
 
6 105.8    
6 121.7 5.33 (1H, m) 
 
7 163.8    
7 31.9   
 
8 103.5    
8 31.9   
 
9 158.9    
9 50.2   
 
10 101.1    
10 36.5   
 
1' 123.0    
11 21.1   
 
2' 130.1  7.70 (1H, d, 9) 
12 39.8   
 
3' 116.6  6.80 (1H, d, 9) 
13 42.3   
 
4' 161.5    
14 56.8   
 
5' 116.6  6.80 (1H, d, 9) 
15 24.3   
 
6' 130.1  7.70 (1H, d, 9) 
16 28.3   
 
1" 103.4  5.26 (1H, s) 
17 56.1   
 
2" 71.9  4.11 (1H, m) 
18 11.9 0.68 (3H, s) 
 
3" 72.0  3.30-3.69 m 
19 19.4 0.99 (3H, s) 
 
4" 72.1  3.30-3.69 m 
20 36.1   
 
5" 67.3  3.30-3.69 m 
21 18.8 0.91 (3H, d, 6.6) 
 
6" 17.6  0.80 (3H, d, 5.4) 
22 34.0   
 
6-CH3 7.8  1.99 (3H, s) 
23 26.1   
 
8-CH3 8.1  2.14 (3H, s) 
24 45.9   
    
25 29.2   
    
26 19.8 0.80 (3H, d, 6.6) 
    
27 19.0 0.82 (3H, d, 6.8) 
    
28 23.1   
    
29 12.0 0.84 (3H, t, 7.2) 
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Table 4.2 NMR spectroscopic data for 8, 10-11 
 
  Compound 8 Compound 10 Compound 11 
position δH (J in Hz) δH (J in Hz) δH (J in Hz) 
6 6.17 (1H, d, 2) 6.10 (1H, d, 2)   
6-CH3     2.00 (3H, s) 
8 6.37 (1H, d, 2) 6.24 (1H, d, 2)   
8-CH3     2.30 (3H, s) 
2' 7.73 (1H, d, 2) 7.60 (1H, d, 1.8) 8.00 (1H, d, 9) 
3'     6.90 (1H, d, 9) 
5' 6.87 (1H, d, 8) 6.73 (1H, d, 8) 6.90 (1H, d, 9) 
6' 7.62 (1H, dd, 2, 8) 7.44 (1H, dd, 1.8, 8) 8.00 (1H, d, 9) 
3-OMe     3.70 (3H, s) 
1"   5.03 (1H, d, 6.6)   
2"   3.70 (1H, m)   
3"   5.52 (1H, m)   
4"   3.77 (1H, d, 2.4)   
5"   3.33 (1H, m)   
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4.3  Activity Assay 
 
TCF/β-catenin transcriptional inhibitory 
The isolated compounds, except 8 (quercetin was used as positive control), were evaluated for their 
TCF/β-catenin transcription activity assay using by STF/293 cells. The viability of STF/293 cells 
was also tested, since a decrease in cell number may contribute to the inhibition. As shown in 
Figure 4.4, 7 (IC50 0.77 μM) and 9 (IC50 0.74 μM) inhibited TCF/β-catenin transcription more than 
11 (IC50 16.6 μM) in a dose-dependent manner, whereas 10 had no significant effect even at high 
concentrations. In this assay, we used quercetin (IC50 30.4 μM), a typical flavonol which is known 
as an inhibitor of TCF/β-catenin transcription, as a positive control.  
 
Cytotoxicity against colon cancer cells 
The effects of 7 and 10 were tested in the human colorectal cancer cell lines against DLD1, SW480, 
and HCT116, in which Wnt signaling is known to be activated, together with 293T cells as a non-
cancer cell line. Cells were exposed to 5, 10, and 20 μM of the compounds. As shown in Figure 4.5, 
7 and 10 exhibited selective cytotoxicity against the three cancer cell lines in dose-dependent 
manner. IC50 values are listed in Table 4.3. The decrease in cell viability caused by 7, which 
disrupted TCF/β-catenin transcription, may be caused by inhibition of the Wnt signaling pathway. 
In fact, 7 was reported to reduce the amount of β-catenin, an important mediator of Wnt signaling, 
in colon cancer cells.
8
 In contrast, the decrease in cell viability caused by 10, which did not inhibit 
TCF/β-catenin transcription, may involve another mechanism. 
 43 
 
 
 
Figure 4.4 Inhibition of TOP assay and cell viability of compounds 7, 9-11. STF/293 cells were 
seeded onto a 96-well plate and then treated with compounds 7, 9-11, in the presence of LiCl. 
Luciferase activity and cell viability were determined at the same time. The bars indicated the s.d. 
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Figure 4.5 Cytotoxicity of compounds 7 and 10 against human embryonic kidney cells (293T) and 
colon cancer cells (DLD1, SW480, HCT116). The bars indicated the s.d.  
 
Table 4.3 IC50 values of cytotoxicity against 293T (human embryonic kidney cells) and colon 
cancer cells (SW480, DLD1, HCT116) 
 
 
 
 
 
In conclusion, five compounds were isolated from Bauhinia malabarica leaves, and examined 
inhibitory effect on Wnt signaling and their cytotoxicity. Finally, 7 showed selective cytotoxicity 
against human colorectal cancer cell lines. On the other hand, 10 did not showed a significant effect 
on Wnt signaling inhibitory activity, even though 10 lead to the selective cytotoxicity activity. In 
addition, 7, 9, and 11 showed the inhibition of TCF/β-catenin transcription activity. 
 
  IC50 values (μM) 
  293T SW480 DLD1 HCT116 
7  >20 18.8 17.5 15.3 
10  >20 18.4 14.1 16 
 45 
 
References 
  1. Kaewamatawong, R.; Kitajima, M.; Kogure, N.; Takayama, H. J. Nat. Med. 2008, 62, 364-
365. 
  2. Songarsa, S.; Rajviroongit, S.; Sae-Tang, D.; Hannongbua, S.; Kirtikara, K.; Kittakoop, P. 
Chem. Biodivers. 2005, 2, 1635-1647.  
  3. Vijayakumari, K.; Siddhuraju, P.; Janardhanan, K. Plant Foods Hum. Nutr. 1993, 44, 291-
298. 
  4. Kongduang, D.; Wungsintaweekul, J.; De-Eknamkul W. Tetrahedron Lett. 2008, 49, 4067-
4072. 
  5. Güvenalp, Z.; Demirezer, L. O. Turk. J. Chem. 2005, 29, 163-169. 
  6. Tran, H. Q.; Nguyen X. C.; Chau, V. M.; Phan, V. K. Nat. Prod. Commun. 2008, 3, 755-758. 
  7. Benyahia, S.; Benayache, S.; Benayache, F.; Quintana, J.; López, M.; LeóN, F.; Hernández, 
J. C.; Estévez, F.; Bermejo, J. J. Nat. Prod. 2004, 67, 527-531. 
  8. Baskar, A. A.; Ignacimuthu, S.; Paulraj, G. M.; AI Numair, K. S. BCM Complement Altern. 
Med. 2010, 10, 24-33. 
 
 
  
 46 
 
Chapter 5 
 
 
Separation of Urginea indica 
 
 
Urginea indica belonging to the family liliaceae, is commonly known as Indian squill. Studied on 
bronchodilator, cardiac stimulant activities,
1
 and antifungal activities
2
 of this plant were reported, 
and this plant contains various flavonoids and steroids.
3,4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Urginea indica 
4
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5.1 Extraction and Isolation 
 
The aerial part of Urginea indica were extracted with MeOH. MeOH extract was subjected to 
Diaion HP20 column chromatography eluting with the Water:MeOH:Acetone gradient system 
(1:0:0 to 0:0:1) to give fraction 1A-1E. Fraction 1D was subjected to chromatography on a silica gel 
with CHCl3:MeOH gradient system (10:1 to 8.5:1.5) resulting seven subfractions. Compound 12 
was isolated through silica gel column of Fr. 2D by elution with Hexane:EtOAc (2:1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Isolation scheme of Urginea indica 
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5.2  Structure Elucidation 
 
Compound (12) was identified as dorstegin on the basis of spectral data analysis.  
 
Dorstegin (12)
5
 
ESIMS m/z 269 [M+H]
+
, 
1
H and 
13
C NMR data, see Table 5.1 
 
Table 5.1 NMR spectroscopic data for 12 (in CD3OD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  Compoudn 12 
position δC δH (J in Hz) 
2 158.2   
3 114.1 6.45 (1H, d, 9) 
4 139 7.98 (1H, d, 9) 
5 112.6   
6 136.9   
7 146.5   
8 118.3   
9 143   
10 108   
2' 143 7.68 (1H, d, 1.8) 
3' 146.5 7.12 (1H, d, 1.8) 
4' 116.7 6.70 (1H, d, 9.8) 
5' 131 5.81 (1H, d, 9.8) 
6'     
Me   1.58 
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Figure 5.3 Structure of compound 12 
 
 
5.3  Activity Assay 
 
TOP activity assay of dorstegin (12) was further evaluated. STF/293 cells were exposed with 5, 10 
μM of 12. 12 inhibited TOP activity assay with IC50 value of 1.2 μM, whereas did not caused 
significance decrease in cell viability of STF/293 cells (Figure 5.4 Left).  
 
Compound 12 was cytotoxic against colon cancer cells (SW480, DLD1, HCT116), in which Wnt 
signaling is abnormally activated, but less affect a normal cell line (Figure 5.4 Right). IC50 values of 
cytotoxicity are shown on Table 5.2. In conclusion, 12 showed inhibition of TOP assay and 
selective cytotoxicity against cancer cells. 
 50 
 
 
 
Figure 5.4 Evaluation of TOP activity and cell viability of compound 12. (Left) STF/293 cells were 
used for TOP assay and cell viability. (Right) Cytotoxicity of compound 12 against human 
embryonic kidney cells (293) and human colon cancer cells (SW480, DLD1, HCT116). The bars 
indicated the s.d. 
 
 
Table 5.2 IC50 values of cytotoxicity against human embryonic kidney cell (293) and colon cancer 
cells (SW480, DLD1, HCT116) 
 
 
 
  
  IC50 values (μM) 
  293 SW480 DLD1 HCT116 
12 >20 13.6 10.6 6.2 
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Chapter 6 
 
 
Mechanism of Wnt Signaling Inhibition  
by Calotropin (4) 
 
 
6.1 Introduction 
 
In the present bioactivity-guide for Wnt signaling inhibition activity, calotropin (4) was isolated 
from Calotropis gigantea. Calotropin (4) was previously isolated from Asclepias curassavica L.
1
 
and reported to show cytotoxicity and reduced anti-apoptotic proteins in K562 erythroleukemia 
cells.
2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Calotropin (4) 
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6.2 Western blot 
 
To elucidate whether calotropin (4) regulates the level of intracellular β-catenin, the protein level 
was examined by western blot analysis. SW480 colon cancer cells were used for further 
investigating which has APC mutation that leads to β-catenin accumulation.3 Cells were treated 
with various concentrations of calotropin (4) for 24 h. As shown in Figure 6.3, calotropin (4) led to 
a significant decrease of cytosolic and nuclear β-catenin levels in a dose-dependent manner. In 
addition, we examined whether calotropin (4) affects the expression of c-myc protein, which is a 
target gene of Wnt signaling. As shown in Figure 6.2, calotropin (4) down-regulated c-myc 
expression. 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Decrease of β-catenin and c-myc protein levels by calotropin (4) 
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Calotropin led to a decrease the protein level of intracellular β-catenin by a proteasomal 
degradation pathway.  
 
Previous work has established that the intracellular β-catenin level is regulated by a proteasomal 
degradation pathway. β-catenin is subjected to tagged for proteolysis by the ligation of multiple 
ubiquitin molecules in a multimeric chain. The poly-ubiquitinated β-catenin is then targeted for 
degradation by the proteasome system.
4
  
 
Accordingly, we investigated the participation of proteasomal degradation in the decrease of β-
catenin by calotropin (4). We used MG-132, a proteasome inhibitor, to inhibit proteasome-mediated 
β-catenin degradation. SW480 cells were pre-incubated with calotropin (4) and 10 μM of MG-132.  
 
 
 
Figure 6.3 β-catenin was accumulated by MG-132 (A) SW480 cells were treated with calotropin (4) 
and MG-132. (B) DLD1 cells were treated with calotropin and MG-132.  
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In Figure 6.3A, calotropin (4) led to a decrease the β-catenin. As expected, the treatment of MG-132 
abrogated the reduction of β-catenin level which caused by calotropin (4). Furthermore, DLD1 cells 
(APC mutation) also showed β-catenin degradation by calotropin (4), whereas MG-132 blocked the 
effect of calotropin (4) (Figure 6.3B). These observations indicated that calotropin (4) induced the 
degradation of β-catenin by proteasome. 
 
 
Calotropin induced β-catenin degradation by GSK3β dependent mechanism. 
 
In Wnt signaling pathway, β-catenin degradation requires GSK3β-mediated phosphorylation at 
Ser33/37/Thr41. Phosphorylated β-catenin is ubiquitinated by the F-box-containing protein β-TrCP 
ubiquitin E3 ligase to be degraded by the proteasome.
4
  
 
To investigate the contribution of calotropin (4) to GSK-3β mediated β-catenin degradation, we 
treated 20 μM of LiCl which inhibit GSK3β activity and stabilize β-catenin, on SW480 colon 
cancer cells. After 24 h incubation, the intact β-catenin and phosphorylated β-catenin protein level 
were analysed by western blot. As a results, no difference between control and LiCl-treated lysates 
(Figure 6.4A, Land 1 and Lane 2). Furthermore, calotropin (4) induced phosphorylation of β-
catenin and led to degradation of β-catenin both absence and presence of LiCl (Figure 6.4A, Lane 3 
and Lane 4). Thus, we increased the concentration of LiCl (100 μM) to observe the distinction of β-
catenin degradation by calotropin (4) between low and high concentration of LiCl.  
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As shown in Figure 6.4B, in the presence of LiCl, β-catenin and phosphorylated β-catenin showed 
no difference compared with control. However, treatment with calotropin (4) enhanced 
phosphorylated β-catenin at Ser33/37/Thr41 and eventually led to decrease of β-catenin. The 
combined treatment of calotropin (4) and LiCl resulted in the recovery of β-catenin level due to 
GSK3β inhibition by LiCl. Moreover, LiCl abolished calotropin (4)-enhanced phosphorylation of β-
catenin at Ser33/37/Thr41, GSK3β phosphorylation sites, with no effects on Ser45 at CK1α 
phosphorylation site. 
 
Figure 6.4 β-catenin degradation by calotropin (4) is dependent of phosphorylation of β-catenin (4) 
by GSK3β. (A) SW480 cells were exposed to 20 μM of LiCl. (B) Cells were exposed to 100 μM of 
LiCl. 
 
In accordance with our western blot data, calotropin (4) significantly increased of protein level of 
phosphorylated β-catenin at Ser45. These results suggested that enhancing the degradation of β-
catenin by calotropin (4) is dependent on CK1α.  
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Calotropin accelerated β-catenin degradation through increase of CK1α levels. 
 
Next, we evaluated the effects of calotropin (4) on CK1α in the destruction complex. CK1α is 
negative regulator as the priming kinase in Wnt signaling pathway. The role of CK1α is inducing 
phosphorylation of β-catenin at Ser45, and subsequently phosphorylated β-catenin at Ser45 are 
phosphorylated at Ser33/37/Thr41 by GSK3β. Consequentially, phosphorylated Ser33 and Ser37 
were recognized by the β-TrCP and leads to β-catenin degradation. We found that calotropin (4) 
increased β-catenin phosphorylation at Ser45. As mentioned above, Ser45 phosphorylation of β-
catenin is caused by CK1α, therefore we next examined whether calotropin (4) induced activation 
of CK1α for the degradation of β-catenin. SW480 cells were treated with calotropin (4) and 100 μM 
of CKI-7, a CK1 inhibitor. As shown in Figure 6.5, addition of calotropin (4) induced the amount of 
CK1α protein level. Consequently, calotropin (4) was able to increase β-catenin phosphorylation at 
CK1α site and eventually phosphorylation of β-catenin at GSK3β sites were induced through 
increased CK1α protein, whereas in the presence of CKI-7, phosphorylation of β-catenin at Ser45 
and Ser33/37/Thr41 were inhibited, and caused obstruction of β-catenin degradation induced by 
calotropin (4).  
 
 
 
 
 
 
 
Figure 6.5 Expression of CK1α induced by calotropin (4) 
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6.3 Small interfering RNA 
 
Next, small interfering RNA (siRNA) against CK1α was used to determine whether CK1α is 
necessary in the calotropin (4) induced degradation of β-catenin. SW480 cells were transfected with 
CK1α-siRNA for 24 h and then incubated with calotropin, and transfection of a non-targeting 
siRNA at the same concentration served as a control. As expected, the treatment with CK1α-siRNA 
resulted in a decrease of CK1α protein levels by half (Figure 6.6A).  
 
As shown Figure 6.6B, the enhanced degradation of β-catenin by calotropin (4) was suppressed 
more by CK1α-siRNA than control-siRNA. Furthermore, combined treatment of calotropin (4) and 
CK1α-siRNA inhibited the phosphorylation of β-catenin at Ser45 (CK1α site) (Figure 6.6C), and 
subsequently that at Ser33/37/Thr41 (GSK3β sites) (Figure 6.6D). Therefore, these results 
suggested that an increase in CK1α contributes to the enhanced degradation of β-catenin by 
calotropin (4) in SW480 cells, and indicated that the increase in CK1α by calotropin (4) enhanced 
the phosphorylation and degradation of β-catenin, which eventually inhibited Wnt signaling.  
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Figure 6.6 Knockdown CK1α obstructed the effect of calotropin (4). SW480 cells were transfected 
with control siRNA and CK1α siRNA for 24 h and then incubated with calotropin (4). On graph, 
vertical axis represents concentration value of protein, with the value for the control set as 1 
arbitrarily.  
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6.4 Real-time RT-PCR 
 
Calotropin also affected in the expression of CK1α mRNA levels. 
 
To further understand the molecular mechanism underlying the Wnt signaling inhibitory effects of 
calotropin (4), we analyzed the mRNA expression of CK1 isoforms (CK1α, CK1δ, and CK1ε) and 
c-myc in SW480 cells using real-time RT-PCR.  
 
     
    
 
Figure 6.7 Regulation of mRNA expression by calotropin in SW480 cells. GAPDH was used as an 
internal control. The bars indicated the s.d. 
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As depicted in Figure 6.7, treatment of calotropin (4) at 5.2 nM elevated the mRNA expression of 
CK1α compared to without calotropin (4) (control). However, calotropin (4) did not affect on CK1δ 
and CK1ε mRNA levels. On the other hand, c-myc, which is a target gene of Wnt signaling pathway, 
showed significantly decreased in the presence of calotropin (4), thereby suggesting that calotropin 
(4) is an effective inhibitor of the Wnt signaling pathway by increasing both CK1α protein levels 
and mRNA levels. 
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6.5  Apoptosis Analysis 
 
As shown in Figure 3.4, we observed cytotoxic effect of calotropin (4) on Wnt-dependent human 
colon cancer cell lines. SW480 cells were used to verify whether the growth inhibition on colon 
cancer cells by calotropin (4) was caused by apoptosis. Co-staining of cells by Annexin-V and 
Propidium iodide was performed to detect apoptosis using flow cytometry.  
 
As demonstrated in Figure 6.9A, when SW480 cells were exposed at different concentrations (2.6, 
5.2 nM) of calotropin (4) for 24 h, early apoptosis was induced. Treatment with 5.2 nM calotropin 
(4) increased early apoptotic cells (lower right) 65.2% versus 0.1% of the control and late apoptotic 
cells (upper right) 9.5% versus 0.1% of the control. The result of time-dependent assay was shown 
in Figure 6.9B. Cells were treated with a fixed concentration (5.2 nM) of calotropin for indicated 
time (12, 24 h), also showed an significant increase of early apoptosis. These results indicated that 
calotropin induced dose and time dependent apoptosis on SW480 cells.  
 
 
 
 
 
 
 
Figure 6.8 Analysis of apoptosis 
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Figure 6.9 Apoptotic cell death induced by calotropin (4). (A) SW480 cells were exposed to 
calotropin (4) for 24 h at concentration of 2.6, and 5.2 nM. (B) Cells were exposed to calotropin (4) 
(5.2 nM) for different time (12, 24 h). The numbers inside each histogram indicate the percentage of 
early apoptotic cells (Annexin V +/PI -) and late apoptotic/necrotic cells (Annexin V +/PI +). 
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To verify whether the apoptosis by calotropin (4) was related with CK1α, calotropin (4) and CKI-7, 
a CK1 inhibitor, was co-incubated in SW480 cells. As shown in Figure 6.10, CKI-7 partly 
suppressed calotropin (4)-induced apoptosis. However, exposure of SW480 cells to the CKI-7 
induced apoptosis despite of CK1α inhibition. Thus, this data showed calotropin (4) induced 
degradation of β-catenin by increasing CK1α, which resulted induction of apoptosis.  
 
 
Figure 6.10 SW480 cells were exposed to 5.2 nM of calotropin (4) and co-incubated with CKI-7 (60 
μM). Cells were stained with PI and Annexin V and subjected to flow cytometric analysis of 
apoptosis. The numbers inside each histogram indicate the percentage of early apoptotic cells 
(Annexin V+/PI-) and late apoptotic or necrotic cells (Annexin V+/PI+). 
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Next, to confirm the involvement of CK1α on calotropin (4) induced apoptosis, siRNA against 
CK1α was used because CKI-7 may contributes not only to CK1α inhibition but also to other 
cellular functions. As shown in Figure 6.11, treatment of calotropin (4) significantly increased early 
apoptosis 56.9% versus 1.6% of without calotropin (4) under control siRNA. However, CK1α 
knockdown condition, treatment of calotropin (4) resulted in slight increase of early apoptosis 18.8% 
versus 1.2% of without calotropin (4). In these results, we showed that increased CK1α, which was 
accelerated by calotropin (4), induced apoptotic cell death. Thus, calotropin (4) inhibited Wnt 
signaling pathway and led to apoptosis in SW480 cells in CK1α-dependent manner. 
 
 
 
Figure 6.11 SW480 cells were transfected with control siRNA and CK1α siRNA for 24 h. Cells 
were exposed to 5.2 nM calotropin (4), and the induction of apoptosis was measured after 24 h. The 
numbers inside each histogram indicate the percentage of early apoptotic cells (Annexin V +/PI -) 
and late apoptotic/necrotic cells (Annexin V +/PI +). 
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6.6 Stability 
 
Stability of protein and mRNA are important in the process of gene expression. The activation of 
mRNAs and proteins are regulated by transcription and translation level.
5
 Additionally, final 
concentration of protein and mRNA related with the ratio of synthesis and degradation. 
 
Expression of CK1α protein and mRNA levels are highly up-regulated in human colon cancer 
SW480 cells by treatment of calotropin (4). We further examined whether the increase of CK1α 
expression is due to the increase of protein and mRNA stability by calotropin (4). To examine the 
effects of calotropin (4), actinomycin D and cycloheximide were used to monitor the stability of 
mRNA and protein. 
 
 
 
 
 
 
 
 
 
Figure 6.10 Structure of cycloheximide and actinomycin D 
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Protein stability 
 
Cycloheximide (CHX) is widely used in biomedical research to inhibit protein synthesis in 
eukaryotic cells studies in vitro. In addition, cycloheximide can be used as an experimental tool in 
molecular biology to determine the half-life of a protein. Treating cells with cycloheximide in a 
time-course experiment followed by western blotting of the cell lysates for the protein of interest 
can show differences in protein half-life.  
 
 
 
 
 
 
 
Figure 6.11 Protein stability of CK1α in SW480 cells. Cells were exposed to calotropin (4) and 
CHX for 0, 3, 6, 12, and 24 h at concentration of 5.2 nM, and 10 μg/mL, respectively. The number 
represents concentration value of protein, with the value for the control set as 1 arbitrarily. 
 
Protein stability was studied by western blot of calotropin (4)-treated SW480 cells with 
cycloheximide (10 μg/mL) in a time-dependent manner (0, 3, 6, 12, and 24 h). As shown in Figure 
6.11, although in the presence of cyclohexamide, the half-life of CK1α protein was about 6 h, 
combined treatment with calotropin (4) and cycloheximide delayed the half-life of CK1α to about 
12 h. 
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 mRNA stability 
 
In cell biology, actinomycin D is shown to have the ability to inhibit transcription. Actinomycin D 
binds to DNA at the transcription initiation complex and preventing elongation of RNA chain by 
RNA polymerase. mRNA half-life can be determined by real-time RT-PCR analysis of RNA 
samples treated with transcriptional inhibitor such as actinomycin D.  
 
To test the contribution of calotropin (4) on mRNA stability, we exposed calotropin (4) and 
actinomycin D on SW480 cells in a time-dependent manner (0, 3, 6, 12, and 12 h). As shown in 
Figure 6.12, the cells treated with actinomycin D alone showed 0.7 folds decrease of CK1α mRNA 
levels at 24 h, whereas combined treatment of calotropin (4) and actinomycin D caused 0.5 folds 
decrease of CK1α mRNA levels at 24 h. 
 
Figure 6.12 mRNA stability of CK1α in SW480 cells. Cells were exposed to calotropin (4) and 
actinomycin D for 0, 3, 6, 12, and 24 h at concentration of 5.2 nM, and 10 μg/mL, respectively. 
 
Taken these result together, above findings suggested that calotropin (4) leads stability of CK1α 
protein and mRNA levels. Consequently, Wnt signaling was inhibited by calotropin (4).  
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Summary 
 
Calotropin was studied on the mechanism of Wnt signaling inhibition. We demonstrated that 
cytosolic and nuclear β-catenin were decreased by calotropin (4) in a dose-dependent manner, and 
the degradation of cytosolic β-catenin by calotropin (4) was inhibited in the presence of MG-132, a 
proteasome inhibitor. These results supported calotropin induced the degradation of β-catenin by 
activating the function of the destruction complex. Therefore, we investigated the mechanism of 
calotropin-induced β-catenin degradation in the destruction complex. 
 
The precise control of β-catenin levels is critical for the regulation of Wnt signaling because 
cytosolic β-catenin translocates to nuclei and serves as a transcriptional activator of target genes. 
Therefore, the phosphorylation of β-catenin in the cytosol and its degradation are important process 
for the inhibition of Wnt signaling. We showed that calotropin (4) decreased β-catenin levels in both 
the cytosol and nuclei and induced the phosphorylation of β-catenin at CK1α/GKS3β sites by 
increasing CK1α protein levels. Moreover, these effects of calotropin (4) were abolished when 
CK1α was inhibited by CKI-7 or the knockdown of CK1α by CK1α-siRNA, and inhibition or 
knockdown of CK1α led to an increase in β-catenin levels. Pyrvinium was reported as an inhibitor 
of Wnt signaling because it activates the CK1α enzyme to regulate the stability of β-catenin and 
Axin in the cytoplasm.
6
 Although pyrvinium activate the CK1α enzyme with no effects on CK1α 
protein levels, calotropin (4) increased CK1α protein levels. Honokiol was recently reported to 
enhance the expression of both CK1α and GSK3β, resulting in the enhanced phosphorylation of β-
catenin at the serine and threonine.
7
 Honokiol increased both CK1α and GSK3β protein levels 
whereas the effects of calotropin (4) increased CK1α protein levels but not on GSK3β. Thus, 
calotropin (4) inhibits Wnt signaling in a different manner from that of pyrvinium or honokiol. 
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The present study showed that calotropin (4) was able to reduce β-catenins level and inhibit the 
growth of Wnt-dependent cells such as DLD1, HCT116, and SW480 cells, but not that of  Wnt-
independent RKO cells. Furthermore, based on western blot, calotropin (4) induced decreasing of 
β-catenin, which is important component to growth and survival of colon cancer cells. However, in 
the presence of calotropin (4), knockdown of the CK1α resulted in increase of β-catenin. These 
results indicated that cytotoxicity of calotropin is related with increased CK1α levels. Wnt signaling 
is known to regulate the early and late stages of apoptosis, and many previous studies have 
demonstrated that the Wnt signaling pathway control apoptosis through various mechanisms.
8
 Flow 
cytometric analysis indicated that calotropin (4) induce apoptosis in SW480 cells. Taken together, 
calotropin (4) increased CK1α protein levels and led to degradation of β-catenin, consquently Wnt 
signaling is inhibited. 
 
Thus, calotropin (4) may be a potential candidate as a therapeutic reagent for Wnt signaling-
dependent cancer. To the best of our knowledge, calotropin (4) is the first small molecule to induce 
the up-regulation of casein kinase 1α protein levels in the Wnt signaling pathway. 
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Chapter 7 
 
 
Experimental 
 
 
7.1 General 
 
Column chromatography : PSQ 100B, FUJI SILYSIA CHEMICAL LTD. 
Chromatorex ODS, FUJI SILYSIA CHEMICAL LTD. 
Diaion HP-20, Mitsubashi Chemical 
Sephadex LH-20, GE healthcare 
Silica gel 60N, Kanto Chemical 
TLC plate   : Kieselgel 60 F254, Merck 
     RP 18 F254, Merck 
Developing reagent  : 10% H2SO4 
Optical rotation   : JASCO P-1020 polarimeter 
UV spectra    : Shimazu UV mini-1240 spectrameter 
NMR spectra   : JEOL ECP400, ECP600, ECS400, ECA600 spectrometers 
     (deuterated solvents, the chemical shift  
of which was used as an internal standard) 
ESIMS    : JEOL JMS-T100LP 
Incubator   : CO2 MCO-17A1, SANYO 37 °C 5% CO2 
Clean bench   : Bio Clean Bench MCV-B131S, SANYO 
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     Bio Clean Bench MCV-B710A TS, SANYO 
Centrifuge   : SORVALLR Biofuge fresco (13000rpm), Kendro 
RT-PCR   : Termal Cycler Dice (TaKaRa) 
      Mx3000P QPCR system (Stratagene) 
 
Cell Culture 
 
STF/293 Human Embryonic Kidney cell  
(provided from Dr. Jeremy Nathans John’s Hopkins university) 
Dulbecco’s modified Eagle Medium (DMEM, high glucose, Wako) + 10% fetal bovine serum (FBS, 
biowest) 
 
293 Human Embryonic Kidney cell 
Eagle’s minimal Essential Medium (EMEM) + 10% FBS 
 
293T Human Embryonic Kidney cell 
DMEM (high glucose, Wako) + 10% FBS 
 
DLD1, HCT116, SW480, RKO colorectal cancer cell 
DMEM (high glucose, Wako) + 10% FBS 
 
Fetal Bovine Serumn (FBS, Biowest), Trypsin EDTA (0.25% Trypsin-EDTA, Gibco), Trypan blue 
(0.4%(w/v) trypan blue, Nacalai tesque Inc.). 
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PBS : 
KCl (Nacalai tesque Inc.)  0.2 g 
KH2PO4 (Nacalai tesque Inc.)  0.2 g 
NaCl (Nacalai tesque Inc.)  8.0 g 
Na2HPO4 (Nacalai tesque Inc.)  1.11 g 
dH2O      up to 1 L (autoclaved; 121℃, 20 min) 
 
 
TCF/β-catenin Transcriptional Assay 
 
pSuperTOPflash    A kind gift from R.T. Moon lab, Washington University 
pSuperFOPflash    A kind gift from R.T. Moon lab, Washington University 
pRL-CMV        Promega 
pTK-Hyg        BD Bio 
Lipofectamine        Invitrogen 
Opti-MEM        Promega 
Cell Culture Lysis Buffer (CCLR) 5X     Promega 
Luciferase 1000 Assay System      Promega 
 Luciferase Assay Substrate 
 Luciferase Assay Buffer 
Passive Lysis Buffer 5X       Promega 
5X PicaGene Dual Cell Culture Lysis Reagent    Toyo Ink, Tokyo 
 5X Cell Lysis Buffer 
 PicaGene Luminescence Reagent 
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 PicaGene Luminescence Substrate 
 Seapansy Luminescence Reagent 
 Seapansy Luminescence Substrate 
 
Lithium Chloride (LiCl)       Wako 
Quercetin        Wako 
Fluorescein diacetate (FDA)      Wako 
 
Western blotting 
 
Electrophoresis apparatus  : BE-201, BIO CRAFT 
      Mini-PROTEAN Tetra Cell, BIO-RAD 
Transfer System    : Trans-Blot SD Semi-DryTransfer cell, BIO-RAD 
      Trans-Blot Tubo, BIO-RAD 
Gel-Blotting Paper   : GE Healthcare Science 
Membrane    : Immun-Blot PVDF membrane, BIO-RAD 
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SDS-PAGE 
 
 
10 X Running Buffer: 
Tris   30.3 g (0.25 M) 
glycin   144 g (1.92 M) 
SDS   10 g (1 % (w/v)) 
dH2O   up to 1 L 
 
Transfer Buffer: 
Tris    2.9 g  (48 mM) 
Glycine    1.5 g  (39 mM) 
MeOH    100 mL  (20% (w/w)) 
dH2O    up to 500 mL 
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5 X Sample Buffer: 
 0.5 M Tris-HCl (pH 6.8)  15.7 mL (0.313 M) 
 SDS    2.5 g  (10% (v/v)) 
 sucrose (Nacalai tesque Inc.) 6.25 g  (25% (v/v)) 
 bromo phenol blue (Kanto) 6.25 mg (0.025% (v/v)) 
 dH2O    up to 25 mL 
 
TBST (Tris-Buffered Saline Tween 20): 
Tris    3.6 g 
NaCl    17.4 g 
conc.HCl   2.4 mL 
Tween 20   3.0 g 
dH2O    up to 3 L 
 
Lysis Buffer: 
1M Tris-HCl    2 mL (20 mM) 
NaCl     878 mg (150 mM) 
Triton X-100    0.5 mL (0.5 % (w/v)) 
sodium deoxycholate   500 mg (0.5 % (w/v)) 
EDTA     292.2 mg (10 mM) 
sodium orthovanadate (Na3VO4)  18.4 mg (1 mM) 
sodium fluoride (NaF)   0.42 mg (0.1 mM) 
protease inhibitor cocktail  1 mL (1 % (v/v)) 
dH2O     up to 100 mL 
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30% Acrylamide: 
Acrylamide    29.2 mg 
N,N’-methylene-bis-acrylamide  0.8 g 
dH2O     up to 100 mL 
 
10% Sodium dodecylsulfate (SDS) 
 SDS     5 g 
 dH2O     up to 50 mL 
 
10% Ammonium persulfate (APS) 
 APS     100 mg 
 dH2O     up to 1 mL 
 
Stripping buffer 
 1 M Tris-HCl (pH 6.8)   3.13 mL (62.5 mM) 
 10% SDS    10 mL (2% (v/w)) 
 2-mercaptoethanol   349 μL (100 mM) 
 dH2O     up to 50 mL 
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7.2 Plant Material 
 
7.2.1 Medicinal Plants Collected from Thailand 
 
The leaves of Bauhinia malabarica was collected from Thailand. Plants was identified by Dr. 
Thaworn Kowithayakorn, and voucher specimen (KKP240) has been deposited in Graduate School 
of Pharmaceutical Sciences, Chiba University (Japan). 
 
 
7.2.2 Medicinal Plants Collected from Bangladesh 
 
The exudates of Calotropis gigantea (KKB050) and Urginea indica (KKB069) were collected from 
Bangladesh in November 2008. Voucher specimens have been deposited in Graduated School of 
Pharmaceutical Sciences, Chiba University (Japan). 
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7.3 TCF/β-catenin transcriptional activity 
 
TOPflash assay, STF/293 cells (3×10
4
) were seeded into 96-well plate. After 24 h incubation, cells 
were treated with 15 mM LiCl and testing samples with growth medium containing FBS (fetal 
bovine serum). An additional 24 h incubation, cells were lysed with CCLR (cell culture lysis 
reagent; 20 μL/well, Promega) and luciferase activities were measured with a Luciferase Assay 
System (Promega) by using Luminoskan Ascent (Thermo). In this assay, quercetin (IC50 30.4 μM) 
was used as an positive control which was known as an inhibitor of TCF/β-catenin transcription.  
 
FOPflash assay, 293T cells (1×10
5
) were split into 24-well plates. Cells were transfected 24 h later 
with 1 μg/well of SuperFOPflash reporter plasmid and 0.025 μg/well of pRL-CMV plasmid for 
internal control using Lipofectamine 2000 (2 μL/well, Invitrogen). After 3 h transfection, testing 
samples were added with FBS containing medium. An additional 24 h is required to lysed in 
Passive lysis buffer (50 μL/well) and luciferase activity was measured with a Dual-Glo Luciferase 
Assay System (Promega). The relative luciferase activities were calculated as a rate of Firefly 
luciferase activity/Renilla luciferase activity. The value of control (DMSO) was normalized to 
100%. 
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7.4 Western Blotting 
 
7.4.1 Isolation of Cellular Extraction 
 
SW480 cells were seeded into 10 cm dishes (2 x 10
6
 cells) and incubated for 24 h at 37 °C. 
Compound was added as various concentrations. After 24 h incubation, cells were washed with PBS 
and then collected by scraping the whole parts. Protein lysate was prepared with lysis buffer (20 
mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5 % sodium deoxycholate, 10 mM EDTA, 1 mM sodium 
orthovanadate, and 0.1 mM NaF) containing 1 % proteasome inhibitor cocktail (Nacalai Tesque, 
Japan), and then centrifuged at 13000 rpm, 4 °C for 30 min.  
 
7.4.2 Isolation of Cytosolic and Nuclear Protein 
 
SW480 cells were seeded into 10 cm dishes (2 x 10
6
 cells) and incubated for 24 h at 37 °C. 
Compound was added and after 24 h incubation, cells were harvested with trypsin and centrifuge at 
1000 rpm at 4 °C for 5 min. Protein lysates were prepared in the same way as the isolation of the 
whole cellular extract. Nuclear and cytosolic extracts were prepared using NE-PER nuclear and 
cytosolic extraction reagent (Pierce) according to the manufacturer’s instructions.  
 
7.4.3 Western Blotting Procedure 
 
Prepared cell lysates were subjected to 10 % and 7.5 % SDS-PAGE electrophoresis then transferred 
to a polyvinylidine difluoride (PVDF) membrane (Bio-Rad).  
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Blots were blocked with TBST (10 mM Tris-HCl pH 7.4, 100 mM NaCl and 0.1 % Tween 20) 
containing 5 % skimmed milk or 3 % bovine serum albumin (BSA) for 1 h and hybridized at room 
temperature for 1 h with primary antibodies: β-actin, β-catenin, GSK3β, and CK1α; for overnight 
with primary antibodies: phospho-β-catenin S45, phosphor-β-catenin S33/S37/T41 (Cell signaling). 
Another 1 h incubation of blots-hybridized secondary antibodies was performed at room 
temperature. The secondary antibodies used were anti-rabbit IgG, anti-mouse IgG (Amersham 
Biosciences), and anti-goat IgG (Sigma). After washing with TBST, immunocomplexed bands were 
detected with ECL Advance Western (GE Healthcare Biosciences) or an Immobilon Western 
(Millipore) detection system.  
Protein lysates of whole extracts, cytosol and nucleus were blotted and blocked using similar 
procedures. 
 
To detect β-catenin (1:2000, 92 kDa) (BD bioscience; 610153), phospho-β-catenin (1:1000, 92 kDa) 
(Cell signaling; 9561, 9564), GSK3β (1:1000, 47 kDa) (Santa Cruz Biotechnology; sc-71186), and 
CK1α (1:1000, 36 kDa) (Santa Cruz Biotechnology; sc-6447), as specific primary antibodies, 
following secondary antibodies were used: anti-rabbit IgG (1:4000), anti-mouse IgG (1:4000) 
(Amersham Biosciences), and anti-goat IgG (1:4000) (Sigma). β-actin (1:4000, 42 kDa) (Sigma) 
was used as an internal control.  
MG132 (Sigma) was added at 10 μM for 12 h, 20 μM and 100 μM of LiCl (Kanto Chemical Co., 
Inc.) was used for 24 h, and CKI-7 (Wako) at 100 μM for 24 h prior to harvesting. 
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7.5 RNA interference Experiments 
 
CK1α siRNA (sc-29912) and control siRNA (sc-37007) were purchased from Santa Cruz. 
Transfection was performed using Lipofectamine 2000 (Invitrogen) in accordance with the 
manufacturer’s protocol. SW480 cells were seeded in 6-well plate at 2 x 105 cells/well. After 24 h, 
cells were transfected with 4 pmol of siRNA using 4 μL of Lipofectamine 2000 for 5 h and 
compound was added to normal growth medium containing siRNA and incubated additional 24 h. 
 
Western blotting was performed to confirm the transfection efficiency of RNA interference. CK1α, 
β-catenin, phospho-β-catenin, and β-actin were used as primary and secondary antibodies, 
respectively, followed by enhanced chemiluminescence detection (Milipore).  
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7.6 Real Time Polymerase Chain Reaction 
 
RT-PCR    : Mx3000P QPCR System, Stratagene 
cDNA Synthesis Reagent  : Takara PCR Thermal Cycler Dice, TaKaRa 
Measuring Instrument   : NanoDrop 2000, Thermo 
 
Extraction of total RNA  
SW480 cells were plated into 24-well plate (1x 10
5
 cells/500 μL), and incubated at 37 °C for 24 h. 
Compound was added and incubate additional 24 h. Cells were washed with PBS and harvested 
using RNeasy Mini Kit (QIAGEN).  
Disrupt the cells by adding 350 μL of Buffer RLT with 1% β-mercaptoethanol. Transfer the cell 
lysate solution to a 1.5 mL collection tube and mix gently by pipetting. Add 350 μL of 70% ethanol 
to the lysate, and mix well by pipetting. Transfer up to 700 μL of the sample, including any 
precipitate, to an RNeasy Mini spin column placed in a 2 mL collection tube. Close the lid, and 
centrifuge for 15 sec at 10,000 rpm. Discard the flow-through. Add 700 μL Buffer RW1 to the 
RNeasy spin column. Close the lid, and centrifuge for 15 sec at 10,000 rpm. Discard the flow-
through. Add 500 μL Buffer RPE to the RNeasy spin column. Close the lid, and centrifuge for 15 
sec at 10,000 rpm. Discard the flow-through. Add 500 μL Buffer RPE to the RNeasy spin column. 
Close the lid, and centrifuge for 2 min at 10,000 rpm. Place the RNeasy spin column in a new 2 mL 
collection tube. Centrifuge at full speed for 1 min to dry the membrane. Place the RNeasy spin 
column in a new 1.5 mL collection tube. Add 30 μL RNase-free water directly to the spin column 
membrane. Close the lid, and centrifuge for 1 min at 10,000 rpm to elute the RNA. RNA yield was 
measured using NanoDrop 2000 (OD260 and OD280). 
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cDNA synthesis 
For a single reaction, combine the following components in a tube on ice. For multiple reactions, 
prepare a master mix without RNA. 
 5 x VILO
TM
 Reaction Mix   2 μL 
 10 x SuperScript
®
 Enzyme Mix   1 μL 
 total RNA     x μL 
 DEPC-treated water    up to 10 μL 
 
 
7.6.1 Reaction Condition 
 
Reverse transcription: 
Incubation    25 °C 10 min 
Reverse transcription reaction 42 °C 50 min 
Deactivation of enzyme  95 °C 15 sec 
 
Primers: 
CK1α;   forward  5’-ATGGTTGGCTTCTTGTCTGC-3’ 
(118 bp product) reverse  5’-TCACTTTAGATGCTGTTATTTCTAGCAC-3’  
CK1δ;   forward  5’-CCCATCGAAGTGTTGTGTAAAGG-3’ 
(106 bp product) reverse  5’-GCCGCAGGTACGAGTAGTCA-3’  
CK1ε;   forward  5’-AAGACGGTGCTGCTCTTGG-3’ 
(99 bp product)  reverse  5’-GAGGAAGTTGTCGGGCTTG-3’  
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c-myc;   forward  5’-GCCACGTCTCCACACTCAG-3’ 
(99 bp product)  reverse  5’-TCTTGGCAGCAGGATAGTCCTT-3’  
Gapdh;   forward  5’-ATGGGGAAGGTGAAGGTCG-3’ 
(68 bp product)  reverse  5’-TAAAAGCAGCCCTGGTGACC-3’  
 
PCR condition: 
Initial incubation  50 °C 2 min 
Initial denaturation  95 °C 2 min 
Denaturation   95 °C 15 sec. 40 cycles 
Annealing, extension  60 °C 30 sec. 
Dissociation curve analysis 60 °C 30 sec. 95 °C 30 sec. 
 
 
7.6.2 real-time RT-PCR Procedure 
 
For multiple reactions, prepare a master mix of common components, add the appropriate volumn 
to each plate well.  
 SYBR
®
 Green ER
TM
 qPCR SuperMix Universal   12.5 μL 
 Primer (forward+reverse)     0.5 μL 
 ROX reference dye *     0.5 μL 
 DEPC-treated water     6.5 μL 
 cDNA       5 μL 
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ROX reference dye* 
ROX is supplied at a 25 μM concentration. Dilute ROX 1:10 immediately before use and make 50 
nM for final concentration.  
 
Master Mix, which included SYBR, primer, ROX, and DEPC-treated water were added at PCR 
plate for 20 μL/well, and 5 μL of cDNA was added. 
Cap the reaction PCR plate, and gently mix. Make sure that all components are at the bottom of the 
plate; centrifuge briefly if needed. PCR plate placed in a real-time instrument and after collected the 
data, results analyzed by ΔΔCT method.  
Total RNA was extracted using an Rneasy Mini kit (Qiagen), and cDNA was synthesized using the 
RT-PCR SuperScript III Platinum Two Step qRT-PCK Kit (Invitrogen). The mRNA level of c-myc, 
CK1α, CK1δ, and CK1ε were measured on a Max3000P QPCR system (Stratagene) at the 
following annealing temperatures:  
50 °C for 2 min (initial incubation), 95 °C for 2 min (initial denaturation), and then 40 cycles of 
95 °C for 15 sec (denaturation) and 60 °C for 30 sec (annealing, extension). Each amplification 
reaction was performed in triplicate. mRNA quantification is expressed in arbitrary units and was 
normalized to an internal control GAPDH.  
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7.7 Apoptosis analysis 
 
Cells were seeded 1 x 10
5 
cells/well in 12-well plates and after 24 hours, cells were treated with 
compound for up to overnight. Cells were harvested by trypsinization and stained using Annexin-V-
FLOUS Staining Kit (Roche), according to the manufacture’s protocol. Then stained cells were 
immediately analyzed by flow cytometry (Millipore, guava easyCyte™) and data analyzed with 
guavaSoft software. Early apoptotic cells with exposed phosphatidylserin but intact cell membranes 
bound to Annexin-V-fluorescein but excluded propidium iodide. Cells in late apoptotic stages were 
labeled with both Annexin-V-fluorescein and propidium iodide. 
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7.8 Protein and mRNA Stability 
 
Protein stability 
SW480 cells were incubated into 6-well plates (1 x 10
6
 cells/well). After 24 h incubation, 
compound was added with cycloheximide (10 μg/mL, Sigma-Aldrich) to inhibit protein 
biosynthesis. Cell extracts were obtained by lysis buffer in time-dependent (0, 3, 6, 12, 24 h). 
Proteins were analysed by SDS-PAGE electrophoresis. 
 
mRNA stability 
Actinomycin D (10 μg/mL, Sigma-Aldrich) was used to inhibit nascent RNA. SW480 cells were 
seeded into 6-well plates (1 x 10
6
 cells/well). After 24 h incubation, compound was added with 
actinomycin D and then cells were lysised for RNA isolation in time-dependent (0, 3, 6, 12, 24 h). 
Collected samples were analysed by RT-PCR.  
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Appendix I 
 
Screening of Thai Plants Extracts 
 
KKP293, 294, 297-301 
 
  
0% 
50% 
100% 
150% 
200% 
KKP 293 KKP 294 KKP 297 KKP 298 KKP 299 KKP 300 KKP 301 
TOP 1 μg/mL TOP 10 μg/mL Viability 1 μg/mL Viability 10 μg/mL 
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Appendix II 
 
Screening of Bangladesh Plants Extracts 
 
KKB124-143 
 
 
0% 
50% 
100% 
150% 
200% 
KKB124 KKB125 KKB126 KKB127 KKB128 KKB129 KKB130 KKB131 KKB132 KKB133 
TOP 10 μg/ml TOP 100 μg/ml Viability 10 μg/ml Viability 100 μg/ml 
0% 
50% 
100% 
150% 
200% 
KKB134 KKB135 KKB136 KKB137 KKB138 KKB139 KKB140 KKB141 KKB142 KKB143 
TOP 10 μg/ml TOP 100 μg/ml Viability 10 μg/ml Viability 100 μg/ml 
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KKB144-153 
 
 
  
KKB154-160, 169, 174, 178 
 
  
0% 
50% 
100% 
150% 
200% 
KKB144 KKB145 KKB146 KKB147 KKB148 KKB149 KKB150 KKB151 KKB152 KKB153 
TOP 10 μg/ml TOP 100 μg/ml Viability 10 μg/ml Viability 100 μg/ml 
0% 
50% 
100% 
150% 
200% 
KKB154 KKB155 KKB156 KKB157 KKB 158 KKB 159 KKB 160 KKB 169 KKB 174 KKB 178 
TOP 10 μg/ml TOP 100 μg/ml TOP 10 μg/ml TOP 100 μg/ml 
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KKB179, 180, 183, 187, 189, 190, 194, 198, 200 
 
 
  
0% 
50% 
100% 
150% 
200% 
KKB 179 KKB 180 KKB 183 KKB 187 KKB 189 KKB 190 KKB 194 KKB 198 KKB 200 
TOP 10 μg/ml TOP 100 μg/ml TOP 10 μg/ml TOP 100 μg/ml 
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Appendix III 
List of Thai Plants Extracts 
 
KKP293  Artocarpus integra (roots) 
KKP294  Streblus asper (leaves) 
KKP297  Millingtonia hortensis (branch) 
KKP298  Millingtonia hortensis (leaves) 
KKP299  Bidens pilosa (whole) 
KKP300  Celastrus paniculata (leaves) 
KKP301  Lophopetalum wallichii (leaves) 
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Appendix IV 
List of Bangladesh Plants Extracts 
 
KKB124  Ipomoea sp. (aerial part) 
KKB125  Wikstroemia indica (aerial part) 
KKB126  Sida acuta (aerial part) 
KKB127  Synedrella nodifloea (aerial part) 
KKB128  Lygodium flexuoaum (aerial part) 
KKB129  Desmodium triquetrum (aerial part) 
KKB130  Croton lobetus (aerial part) 
KKB131  Elephantopous scaber (aerial part) 
KKB132  Urena lobata (aerial part) 
KKB133  Melastoma malabathricum (aerial part) 
KKB134  Ziziphus oenoplea (aerial part) 
KKB135  Thysanolaena maxima (aerial part) 
KKB136  Solanum indicum (aerial part) 
KKB137  Spilanthes acemella (aerial part) 
KKB138  Eupatorium odoratum (aerial part) 
KKB139  Microcos paniculata (aerial part) 
KKB140  Lantana camera (aerial part) 
KKB141  Achyranthes aspera (aerial part) 
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KKB142  Ocimum sanctum (aerial part) 
KKB143  Cajanuus cajan (leaves) 
KKB144  Allamanda spp. (aerial part) 
KKB145  Anisomeles indica (aerial part) 
KKB146  Hibiscus surattensis (aerial part) 
KKB147  Ipomea pescapra (aerial part) 
KKB148  Tecoma stans (aerial part) 
KKB149  Clinogyne dichotoma (leaves) 
KKB150  Flemingia congesta (leaves) 
KKB151  Ardisia humilis (leaves) 
KKB152  Ecbolium linnaenum (leaves) 
KKB153  Polygonum lanatum (leaves) 
KKB154  Costus specious (leaves) 
KKB155  Sonneratia apetala (fruit stalk) 
KKB156  Gendarussa vulgaris (leaves) 
KKB157  Nymphea nouchali (roots) 
KKB158  Sida rhombifolia (aerial part) 
KKB159  Bacopa monnieri (whole) 
KKB160  Rumex maritimus (aerial part) 
KKB169  Azadirachta indica (leaves) 
KKB174  Ipomoea mauritiana (stem) 
KKB178  Manihot esculenta (stem) 
KKB179  Manihot esculenta (leaves) 
KKB180  Coccinea cordifolia (stem) 
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KKB183  Ficus benghalensis (roots) 
KKB187  Cyperus rotundus (leaves) 
KKB189  Terminalia arjuna (bark) 
KKB190  Sida cordifolia (leaves) 
KKB194  Datura metel (leaves) 
KKB198  Ficus religiosa (leaves) 
KKB200  Ficus religiosa (bark) 
  
  
 
  
 98 
 
Acknowledgements 
 
I would like to express my deepest appreciation to my Ph.D supervisor, Professor Masami 
ISHIBASHI, for not only allowing me to work in his laboratory (Natural Products Chemistry 
Laboratory, Graduate School of Pharmaceutical Sciences, Chiba University, Japan) but also for his 
valuable and constructive suggestions during my research work.  
 
My deepest heartfelt also goes to Assoc. Prof. Midori A. ARAI for her valuable discussion and 
guidance. Also, I would like to thank Assit. Prof. Kazufumi TOUME, who was always willing to 
help and give his best suggestions during the research.  
 
I am grateful to my committee members, Prof. Hiromitsu TAKAYAMA, Prof. Atsushi NISHIDA, 
and Prof. Motoyuki ITOH for spending their time on careful reading of my thesis as well as for 
their valuable comments. 
 
I also express sincere appreciation to Prof. Yong-Soo KWON, College of Pharmacy, Kangwon 
National University, Korea, for his motivation and encouragement.  
 
Special gratitude also goes to all my past and present members of Natural Products Chemistry 
Laboratory, who made the lab a friendly environment for working and the precious memory for me. 
  
 
 99 
 
I acknowledge financial support from Japan Government (Monbukagakusho): Ministry of 
Education, Science and Culture, Sports, Science and Technology (MEXT), that enable me to finish 
Ph.D study and research in Chiba University.  
 
Last but not the least, I would like to thank my family for their affection, patience, support and 
encouragement for years: my father Dr. Chun-Keun PARK, mother Young-Sun JANG, and brother 
Sung-Hyun PARK. Without their persistent support, this dissertation would not have been possible.  
 
 
  
 100 
 
Publications 
 
 
1. Park, H. Y.; Toume, K.; Arai, M. A.; Koyano, T.; Kowithayakorn, T.; Ishibashi, M.  J. Nat. 
Med. 2014, 68, 242-245. 
  
 101 
 
Honorable Referees 
 
 
This dissertation was evaluated by the following committee authorized by the Graduate School of 
Pharmaceutical Sciences, Chiba University.  
 
1. Professor Hiromitsu TAKAYAMA   Chairman 
  Graduate School of Pharmaceutical Sciences 
 
2. Professor Atsushi NISHIDA    Member 
  Graduate School of Pharmaceutical Sciences 
 
3. Professor Motoyuki ITOH    Member 
  Graduate School of Pharmaceutical Sciences 
 
 
